Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,699.38
(
1.01%
)
US TECH 100
23,895.60
(
-0.50%
)
Dow Jones
46,946.41
(
0.83%
)
Brent Oil
101.04
(
2.78%
)
Bitcoin
74,396.60
(
-0.60%
)
News Focus
News Focus
Post# of 257250
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: floblu14 post# 83528

Thursday, 02/24/2011 2:59:32 PM

Thursday, February 24, 2011 2:59:32 PM

Post# of 257250
Copaxone was mentioned in passing on MYL’s 4Q10 CC today.* COO Heather Bresch confirmed that the 30-month Hatch-Waxman stay on MYL’s Paragraph-IV challenge runs out in Mar 2012. We already knew this date by simple arithmetic insofar as the FDA accepted MYL’s Copaxone ANDA for review in Sep 2009 (#msg-41441618), when MYL notified Teva of the Paragraph-IV challenge triggering the start of the 30-month clock.

MYL’s 4Q10 PR:
http://investor.mylan.com/releasedetail.cfm?ReleaseID=552326

MYL’s 4Q10 CC slides:
http://investor.mylan.com/common/download/download.cfm?companyid=ABEA-2LQZGT&fileid=443927&filekey=b7c8185d-6856-4463-8eba-e44efdc2b43e&filename=MYLAN%20Q4%202010%2002._24_2011.pdf

*The reference was so fleeting I missed it on the first listen.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now